EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review

Jenny Linnea Victoria Lindroos iD, Marte-Helene Bjørk iD, Nils Erik Gilhus

Journal of Clinical Medicine · 17.02.2024 · 13 (4) · 1136

DOI: 10.3390/jcm13041136 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.02.2024. Verfasst von Jenny Linnea Victoria Lindroos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myasthenia gravis (MG) is a rare autoimmune disease. Transient neonatal myasthenia gravis (TNMG) is caused by pathogenic maternal autoantibodies that cross the placenta and disrupt signaling at the neuromuscular junction. This is a systematic review of this transient immunoglobulin G (IgG)-mediated disease. TNMG affects 10–20% of children born to mothers with MG. The severity of symptoms ranges from minor feeding difficulties to life-threatening respiratory weakness. Minor symptoms might go unnoticed but can still interfere with breastfeeding. Acetylcholine-esterase inhibitors and antibody-clearing therapies such as immunoglobulins can be used to treat TNMG, but most children do well with observation only. TNMG is self-limiting within weeks as circulating antibodies are naturally cleared from the blood. In rare cases, TNMG is associated with permanent skeletal malformations or permanent myopathy. The mother’s antibodies can also lead to spontaneous abortions. All healthcare professionals meeting pregnant or birthing women with MG or their neonates should be aware of TNMG. TNMG is hard to predict. Reoccurrence is common among siblings. Pre-pregnancy thymectomy and intravenous immunoglobulins during pregnancy reduce the risk. Neonatal fragment crystallizable receptor (FcRn) blocking drugs for MG might reduce TNMG risk.

Schlagwörter

Stichwörter der Autor:innen

MuSK antibodiesacetylcholine receptor antibodiesautoantibodiesmaternal–fetal exchangemyasthenia gravisneonatal diseaseneuromuscular junction

Autor:innen und Institutionen

  • Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway.
  • Department of Neurology, Haukeland University Hospital, 5053 Bergen, Norway.

ORCID-Profile: Jenny Linnea Victoria Lindroos, Marte-Helene Bjørk

Zitieren

APA

Lindroos, J. L. V., Bjørk, M. H., & Gilhus, N. E. (2024). Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review. Journal of Clinical Medicine, 13(4), 1136. https://doi.org/10.3390/jcm13041136

Vancouver

Lindroos JLV, Bjørk MH, Gilhus NE. Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review. Journal of Clinical Medicine. 2024;13(4):1136. doi:10.3390/jcm13041136

BibTeX
@article{Lindroos2024,
  author = {Lindroos, Jenny Linnea Victoria and Bjørk, Marte-Helene and Gilhus, Nils Erik},
  title = {Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {1136},
  doi = {10.3390/jcm13041136}
}
Kostenlos starten →